Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

Two patients present with pink plaques on different parts of their head and face. Can you correctly identify each case?

Immunosuppression was identified as a significant independent predictor of poor outcomes among patients with cutaneous squamous cell carcinoma.

Subcutaneous infliximab therapy alone is associated with higher immunogenicity than IV infliximab and an immunomodulator combined.

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

Patients with metastatic melanoma in mitochondrial haplogroup T are significantly less likely to respond to immunotherapy.